A Phase 2 interventional study of Diazepam in Epilepsy, sponsored by Acorda Therapeutics. Completed at 4 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-03-29.
Sponsored by Acorda Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing diazepam in Epilepsy — none open to participants now, none under way, none of them phase 3. Diazepam · Epilepsy.
Among the 10 studies testing diazepam in Epilepsy, this one is the 8th largest by enrollment, is one of 2 that started in 2011, is one of 3 in phase 2, and was the 4th registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →None of the 10 studies testing diazepam in Epilepsy is open now. The open studies under Epilepsy, anywhere →
Diazepam: first FDA approval 1963 (VALIUM). What it is approved for, and how studies give it, is on its page →
Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 3
First in 1995; this study’s year is marked. 2 started in 2011.
This study's enrollment of 31 is below the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 68 across the 10 interventional studies. Of the 9 that completed or were terminated, 8 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 10 have an industry lead sponsor. The 6 most frequent:
Acorda Therapeutics is the lead sponsor of 38 studies on the registry; none are open to participants now.
Acorda Therapeutics has 3 studies filed under Epilepsy — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing diazepam in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the pharmacokinetics of Diazepam Nasal Spray following a single dose in epileptic patients experiencing a seizure episode.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Diazepam
single-dose; dosage in mg, based on patient body weight
Pharmacokinetic (PK) Parameter: Maximum Measure Plasma Concentration (Cmax),
Summary of Dose-Adjusted Diazepam and Nordiazepam PK parameter Cmax. The mean Cmax value was adjusted to a 20 mg dose.
Time frame: Pre-dose, 10, 15, 30, and 45 mins, and 1, 1.5, 2, 4, 6, 9,and 12 hours
Pharmacokinetic (PK) Parameter: Time to Maximum Plasma Concentration (Tmax)
Summary of Dose-Adjusted Diazepam and Nordiazepam PK parameter Tmax. The mean Tmax value was adjusted to a 20 mg dose.
Time frame: Pre-dose, 10, 15, 30, and 45 mins, and 1, 1.5, 2, 4, 6, 9,and 12 hours
Pharmacokinetic (PK) Parameter: Area Under The Concentration Curve From Time 0 to 12 Hours (AUC(0-12)) and AUC Time to Last Measurable Plasma Concentration
Summary of Dose-Adjusted Diazepam and Nordiazepam PK parameter AUC(0-12) and AUC(last). The mean estimate of AUC(0-12) was adjusted to a 20 mg dose. AUC(last) was used for the calculation of AUC for nordiazepam. AUC(0-12) values could not be estimated for nordiazepam given that nordiazepam concentrations were rising between 6 and 12 hours.
Time frame: Pre-dose, 10, 15, 30, and 45 mins, and 1, 1.5, 2, 4, 6, 9,and 12 hours
Number of Patients With Treatment Emergent Adverse Events (TEAEs)
TEAEs refer to adverse events with start dates occurring after dosing. Treatment-Related TEAEs refer to those 'possibly' or 'probably' related to study drug. Intensity definitions: * Mild: Usually transient, required no special treatment, and did not interfere with the patient's daily activities. * Moderate: Usually caused a low degree of inconvenience or concern to the patient, and may have interfered with daily activities, but was usually ameliorated by simple therapeutic measures. * Severe: Interrupted a patient's usual daily activities, and generally required systemic drug therapy or other treatment.
Time frame: Pre-dose to 48 hours post-dose
| Milestone | Diazepam Nasal Spray |
|---|---|
| Started | 31 |
| Completed | 30 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
Summary of Dose-Adjusted Diazepam and Nordiazepam PK parameter Cmax. The mean Cmax value was adjusted to a 20 mg dose.
| nanogram/milliliter (ng/mL) | Diazepam Nasal Spray | Nordiazepam |
|---|---|---|
| Pharmacokinetic (PK) Parameter: Maximum Measure Plasma Concentration (Cmax), | 208 ± 90.3 | 23.9 ± 16.5 |
TEAEs refer to adverse events with start dates occurring after dosing. Treatment-Related TEAEs refer to those 'possibly' or 'probably' related to study drug. Intensity definitions: * Mild: Usually transient, required no special treatment, and did not interfere with the patient's daily activities. * Moderate: Usually caused a low degree of inconvenience or concern to the patient, and may have interfered with daily activities, but was usually ameliorated by simple therapeutic measures. * Severe: Interrupted a patient's usual daily activities, and generally required systemic drug therapy or other treatment.
| participants | Diazepam Nasal Spray |
|---|---|
| Subjects with one or more TEAEs | 28 |
| Total number of TEAEs | 96 |
| Subjects with one or more Treatment-Related TEAEs | 21 |
| Total number of Treatment-Related TEAEs | 56 |
| Subjects with one or more Severe TEAEs | 1 |
| Total number of Severe TEAEs | 1 |
| Total number of Moderate TEAEs | 24 |
| Total number of Mild TEAEs | 71 |
Summary of Dose-Adjusted Diazepam and Nordiazepam PK parameter Tmax. The mean Tmax value was adjusted to a 20 mg dose.
| hour (h) | Diazepam Nasal Spray | Nordiazepam |
|---|---|---|
| Pharmacokinetic (PK) Parameter: Time to Maximum Plasma Concentration (Tmax) | 0.98 ± 0.86 | 11.10 ± 2.14 |
Summary of Dose-Adjusted Diazepam and Nordiazepam PK parameter AUC(0-12) and AUC(last). The mean estimate of AUC(0-12) was adjusted to a 20 mg dose. AUC(last) was used for the calculation of AUC for nordiazepam. AUC(0-12) values could not be estimated for nordiazepam given that nordiazepam concentrations were rising between 6 and 12 hours.
| hour*nanogram/milliliter (h*ng/mL) | Diazepam Nasal Spray | Nordiazepam |
|---|---|---|
| AUC(0-12) | 1227 ± 488 | NA ± NA |
| AUC(last) | NA ± NA | 192 ± 148 |
Collected over Pre-dose to 48 hours post-dose. Non-serious events are listed at a 3.2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Diazepam Nasal Spray | — | 0/31 (0%) | 28/31 (90.3%) |
| Event | Diazepam Nasal Spray |
|---|---|
| HeadacheNervous system disorders | 16/31 |
| DysgeusiaNervous system disorders | 8/31 |
| Nasal discomfortRespiratory, thoracic and mediastinal disorders | 7/31 |
| SomnolenceNervous system disorders | 5/31 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 5/31 |
| NauseaGastrointestinal disorders | 5/31 |
| Lacrimation increasedEye disorders | 5/31 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 4/31 |
| Paranasal sinus hypersecretionRespiratory, thoracic and mediastinal disorders | 4/31 |
| Tongue injuryInjury, poisoning and procedural complications | 4/31 |
Safety Population Number (N)=31 Pharmacokinetic Population N=30
| Age, Continuous(years) | Diazepam Nasal Spray |
|---|---|
| Mean | 35.2 ± 12.80 |
| Sex: Female, Male(Participants) | Diazepam Nasal Spray |
|---|---|
| Female | 18 |
| Male | 13 |
| Ethnicity (NIH/OMB)(Participants) | Diazepam Nasal Spray |
|---|---|
| Hispanic or Latino | 3 |
| Not Hispanic or Latino | 23 |
| Unknown or Not Reported | 5 |
| Body Mass Index (BMI)((kg/m^2)) | Diazepam Nasal Spray |
|---|---|
| Mean | 26.3 ± 4.08 |
The record gives a start of Sep 2011, a primary completion of Feb 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 4 years 1 month after primary completion. A results delay was requested in Jan 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Diazepam